Brief Effect of a Small Hydrophobic Drug (Cinnarizine) on the Physicochemical Characterisation of Niosomes Produced by Thin-Film Hydration and Microfluidic Methods by Yeo, Li Key et al.
Yeo, Li Key, Olusanya, Temidayo O.B., Chaw, Cheng and Elkordy, Amal (2018) 
Brief Effect of a Small Hydrophobic Drug (Cinnarizine) on the Physicochemical 
Characterisation of Niosomes Produced by Thin­Film Hydration and Microfluidic 
Methods. PHARMACEUTICS, 10 (4). 
Downloaded from: http://sure.sunderland.ac.uk/id/eprint/10054/
Usage guidelines
Please   refer   to   the  usage guidelines  at  http://sure.sunderland.ac.uk/policies.html  or  alternatively 
contact sure@sunderland.ac.uk.

pharmaceutics
Article
Brief Effect of a Small Hydrophobic Drug
(Cinnarizine) on the Physicochemical
Characterisation of Niosomes Produced by Thin-Film
Hydration and Microfluidic Methods
Li Key Yeo, Temidayo O. B. Olusanya, Cheng Shu Chaw and Amal Ali Elkordy *
School of Pharmacy and Pharmaceutical Sciences, University of Sunderland, Sunderland SR1 3SD, UK;
li-key.yeo@research.sunderland.ac.uk (L.K.Y.); temmywood@yahoo.com (T.O.B.O);
cheng.chaw@sunderland.ac.uk (C.S.C.)
* Correspondence: amal.elkordy@sunderland.ac.uk; Tel.: +44-0-191-515-2576
Received: 20 July 2018; Accepted: 9 October 2018; Published: 13 October 2018


Abstract: Novel niosomal formulations containing cinnarizine were developed to enhance its drug
characteristics. In this work, niosomes (non-ionic surfactant vesicles) were prepared by conventional
thin-film hydration (TFH) and microfluidic (MF) methods with sorbitan monostearate (Span® 60),
cholesterol, and co-surfactants (Cremophor® ELP, Cremophor® RH40 and Solutol® HS15) as key
excipients. The aim was to study the effect of cinnarizine on the characteristics of different niosomal
formulations manufactured by using different methods. For effective targeted oral drug delivery,
the efficacy of niosomes for therapeutic applications is correlated to their physiochemical properties.
Niosome vesicles prepared were characterised using dynamic light scattering technique and the
morphology of niosomes dispersion was characterised using optical microscopy. Dialysis was carried
out to purify niosome suspensions to determine drug loading and drug release studies was performed
to study the potential use of niosomal systems for cinnarizine.
Keywords: niosome; cinnarizine; poorly water-soluble drug; thin-film hydration; microfluidic;
co-surfactants
1. Introduction
Niosomes are non-ionic surfactant-based bilayer membrane vesicles that are formed by
self-assembly upon hydration. Non-ionic surfactants are amphiphilic molecules that are biodegradable,
biocompatible, and non-immunogenic. Niosomes are capable of entrapping both hydrophobic and
hydrophilic drugs [1]. They have been successfully manufactured for oral delivery of cytotoxic agents
such as paclitaxel [2] at a lower cost with various surfactant combinations by film hydration method.
The potential use of niosomes as an oral delivery system has been studied to overcome the challenges
of limited absorption due to poor drug stability and poor water solubility in the gastrointestinal
tract [3,4]. Niosomes are similar to liposomes (which are comprised of phospholipids) as drug delivery
systems. Unlike liposomes, niosomes have less chemical instability problems, but they are associated
with physical stability issues such as fusion, aggregation, sedimentation, and drug leakage during
storage [3]. Numerous studies have shown that niosomes have a high potential as a carrier for poorly
water-soluble drugs such as paclitaxel [2], valsartan [5], candesartan [6], lornoxicam [7], diacerein [8],
griseofulvin [9], flurbiprofen [10], and diclofenac [11].
Spans are the product name marketed for sorbitan esters; they are produced by the dehydration of
sorbitol. The hydrophile-lipophile balance (HLB) value of Span decreases with increasing the length of the
alkyl chain (increasing the number of fatty acid groups); for example, sorbitan monostearate (Span® 60)
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has an HLB value of 4.7 and sorbitan tristearate (Span® 65) has an HLB value of 2.1; sorbitan monooleate
(Span® 80) has an HLB value of 4.3, and sorbitan trioleate (Span® 85) has an HLB value of 1.8.
Their gel transition temperature increases as the length of the acyl chain increases resulting in
decreased leakage of drugs from niosomes [12]. All Spans have the same head group and different alkyl
chain length [13]. As the alkyl chain length increases, the entrapment efficiency of hydrophobic drugs
is expected to increase. The encapsulation efficiency (%EE) is decreasing from Span® 60 (C18), Span®
40 (C16), Span® 20 (C12), and Span® 80 (unsaturated C18). This was in an agreement with flurbiprofen
pro-niosomes studied by Mokhtar et al. [10]. In addition, the study found that with increasing total
lipid or drug concentration use resulted in an increased %EE of the flurbiprofen produced. Sorbitan
monostearate (Span® 60) with a C18 chain has a gel transition temperature of 56–58 ◦C and an HLB
value of 4.7, exhibits the highest entrapment efficiency, therefore it was chosen for this current study.
The molar ratio of cholesterol incorporated with surfactants may affect the entrapment of drugs into
niosomes. Nasseri [14] reported that the equimolar mixture (Span® and cholesterol) represented the
critical composition as there is only one hydrogen bonding group on the cholesterol moiety to interact
with oxygen functionalities on the Span® 60, resulting in an increase in membrane cohesion.
The incorporation of cholesterol with surfactants of lower HLB values has shown to promote
the gel liquid transition temperature of the vesicle [15]. Kumar and Rajeshwarrao [12] reported the
addition of cholesterol enables more hydrophobic surfactants (lower HLB values) to form niosomes
by suppressing the tendency of aggregation. Cholesterol helps by increasing the orientation order
of their relatively mobile hydrocarbon chains of liquid-crystalline phospholipid bilayers, decreasing
bilayer permeability and reducing the efflux of the entrapped drug. This resulted in prolonged drug
retention [16] and effectively prevented leakage of the drug from niosomes [13].
Other additive agents to enhance the characteristics of the niosome vesicles are co-surfactants.
Co-surfactants are usually more hydrophilic; therefore, they act as emulsifying, solubilizing, and
wetting agents as they have generally a higher HLB value from 12 to 16 and a higher molecular weight
of over 1000 Da. Co-surfactants are commonly used in the literature for niosome formulations, for
example Cremophor® ELP (purified polyoxyl 35 castor oil) [17], Cremophor® RH40 (hydrogenated
polyoxyl 40 castor oil) [18], and Solutol® HS15 (polyoxyl 15 hydroxystearate) [19]. Solutol® HS15 is
known to inhibit P-glycoprotein, which is an ATP-dependent pump that is responsible for reducing
drug intestinal absorption by efflux transportation. Addition of this agent has shown to enhance
paclitaxel aqueous solubility and permeability across Caco-2 monolayer cell without inducing
cytotoxicity [17]. This would further enhance oral bioavailability of drugs such as cinnarizine (in this
study) in the niosomal formulations.
There are numerous studies which have investigated the preparation of niosomes using the
conventional thin-film hydration method and the reverse phase evaporation technique. The formation
of film by evaporation of organic solvent is followed by hydration to produce multi-lamellar vesicles
which are non-reproducible and a post size reduction process is needed to generate homogenous
vesicles [18]. Compared to the conventional bulk method, microfluidic technique has been used to
prepare lipid-based nanoparticles and liposomes to generate reproducible small-sized nanoparticles
for drug encapsulation. Correia et al. [19] reported that microfluidic systems step up in the area of drug
delivery with promising features that allow control of particle size and increased stability of the final
liposome products. Hence, this technique will be used in this current research for niosome production.
Cinnarizine is a piperazine derivative with antihistaminic, sedative, antiserotonergic,
antidopaminergic, and calcium channel blocking activities [20]. It is also used as cerebral blood
flow improver in the management of various peripheral and cerebral vascular disorders. Cinnarizine
is a lipophilic weak base (literature pKa values of 1.95 and 7.47) and a log P of 5.6 [21]. The drug
is practically insoluble in water in its unionized form and has a narrow absorption window. After
oral administration of conventional tablet formulations, absorption is relatively slow, peak serum
concentrations occurring after 2.5 to 4 hours [22] from the upper gastrointestinal tract. This is due to
patients’ gastric acidity influence on the dissolution and absorption of cinnarizine.
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The study was aimed to develop and characterize cinnarizine-containing niosomes prepared
by thin-film hydration and microfluidic methods, with the future aim to coat the niosome vesicles
manufactured with a muco-adhesive agent (chitosan) for a prolonged drug retention in the stomach
(to enhance drug bioavailability). To the best of our knowledge, there are no literature available
for formulation of cinnarizine in niosome systems using either thin-film hydration or microfluidic
methods, hence it is worth to characterize niosomes with this hydrophobic drug.
2. Experimental Section
2.1. Materials
Cinnarizine, Span® 60 (S60), cholesterol (Cho), phosphate buffered saline (PBS) tablets, chloroform,
ethanol, hydrochloric acid 37%, and isopropanol were purchased from Sigma-Aldrich (Dorset, UK).
Cremophor® ELP (ELP), Cremophor® RH40 (RH40), and Solutol® HS15 (HS15) were obtained from
BASF (Cheshire, UK). All materials and chemicals were of analytical grade and used as received.
2.2. Preparation of Niosomes
In conventional thin-film hydration method, weighed lipids (refer to Table 1) and cinnarizine
were dissolved in chloroform and then transferred into a 100 mL round-bottomed flask. The formation
of film was produced by using the rotary evaporator (Buchi rotavapor R-210, Flawil, Switzerland) to
remove chloroform under pressure of 325 ± 10 mbar at 60 ◦C in a water bath and 100 revolutions
per minute (rpm). Afterwards, the thin film obtained was allowed to dry completely and cooled
at room temperature before underwent hydration process with 20 mL of phosphate buffered saline
(PBS 10 mM, pH 7.4) solution using water bath shaker at 60 ◦C and 100 rpm for 30 min to produce
niosome suspensions. Size reduction step (e.g., sonication) was excluded to investigate the influence
of preparation methods on niosome characteristics.
Table 1. Compositions of niosomal formulations (initial total lipid content of 10 mg/mL and initial
drug content of 0.5 mg/mL).
Formulation Code Composition (mg) % Molar Ratio Cinnarizine Total LipidContent (mg)
F1 Span
® 60: cholesterol
105.4:94.6
50:50 − 200
F2 Span
® 60: cholesterol
105.4:94.6
50:50 + 200
F3 Span
® 60: cholesterol: Cremophor® ELP
73.0:65.6:61.4
45:45:10 − 200
F4 Span
® 60: cholesterol: Cremophor® ELP
73.0:65.6:61.4
45:45:10 + 200
F5 Span
® 60: cholesterol: Cremophor® RH40
61.6:55.2:83.2
45:45:10 − 200
F6 Span
® 60: cholesterol: Cremophor® RH40
61.6:55.2:83.2
45:45:10 + 200
F7 Span
® 60: cholesterol: Solutol® HS15
81.8:73.2:45.0
45:45:10 − 200
F8 Span
® 60: cholesterol: Solutol® HS15
81.8:73.2:45.0
45:45:10 + 200
As for microfluidic method, NanoAssemblrTM Benchtop system (Precision NanoSystems Inc.,
Vancouver, VAN, Canada) with a microfluidic cartridge and a heating block controller was used.
Weighed lipids (refer to Table 1) and cinnarizine (without cinnarizine for empty pre-formed niosomes)
were dissolved in ethanol to be used as organic phase and aqueous phase used was PBS. Process
parameters applied were flow rate ratio of 4:1 (aqueous:organic), a total flow rate of 12 mL/min, and
at 60 ± 1 ◦C (these conditions have been used based on preliminary studies).
A modified dialysis method from reference [23] was used for all niosome suspensions prepared
to be dialysed (using a dialysis membrane, MWCO: 3500 Da) against 1 L of 0.1 M hydrochloric acid
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solution (HCl, pH 1.2) under magnetic stirring for overnight to remove non-entrapped free drug and
any trace of organic solvent.
2.3. Morphological Analysis of Niosomes Using Optical Microscope
Freshly prepared niosome suspensions were observed under light microscope with magnification
lens of 40× using a MicroCam Olympus BH-2/LB with AxioCam MRc (Carl ZEISS, Jena, Germany).
The formations of niosomes were confirmed by observation under optical light microscope and
real-time images were taken. The niosomes formed were all in a distinctive round, circular shape.
2.4. Fourier-Transform Infra-Red (FTIR) Spectroscopy
Purified niosome pellets obtained from centrifugation (15,000 rpm for 20 min at 4 ◦C) were
re-dispersed with 5 mL deionised water (TFH-based niosomes) and 5% mannitol (MF-based niosomes),
and then kept in an ultra-low freezer (−80 ◦C) for 2 h prior to the freeze-drying process using
Christ Advance Alpha 2–4 LSCplus freeze dryer, Osterode, Germany. The vacuum was set to
0.035 mbar with ice condenser set at −81 ◦C and shelf temperature at 10 ◦C. The infrared spectra of
individual material and freeze-dried niosome samples were taken using a Shimadzu IRAffinity-1S
spectrophotometer (Shimadzu UK Ltd., Buckinghamshire, UK). The spectra were recorded using
12 scans in the wavelength range (4000–550 cm−1) with a resolution of 4 cm−1 to study their possible
interactions using the Shimadzu LabSolutions IR. Under the same conditions, the infrared spectrum of
the cinnarizine pure drug was also taken for identification of its principle functional groups.
2.5. Thermal Characteristics of Niosomes
A standard mode DSC conditioning was performed at 75 ◦C for 120 min hold time without a
refrigerated cooling system (RCS) (DSC Q1000 TA Instruments, Ghent, Belgium) with empty cell
chamber. Afterwards, temperature calibration was carried out using pure indium with the RCS.
All freeze-dried niosome samples (refer to Section 2.4) weighed between 2 and 8 mg using Mettler
MT5 balance (Mettler Toledo, Leicester, UK) were placed within standard aluminium hermetic pans
and lids for DSC runs. DSC runs were performed at a heating rate of 10 ◦C/min from 25–300 ◦C.
The nitrogen gas flow rate was 50 mL/min with the RCS on. Thermal Universal Analysis 2000 was
used to perform analysis of the obtained DSC thermograms.
2.6. Particle Size, Polydispersity, and Charge of Niosomes
An aliquot from each of the freshly prepared niosome suspensions was used for measurement
of particle size, polydispersity index (PDI), and zeta potential (ZP) in 1/20 dilution with deionised
water, using Malvern Zetasizer Nano ZSP (Cambridge, UK). Measurement angle of 173◦ backscatter
was used for angle of measurement detection. Three measurements were taken for each sample.
Hydrodynamic size and PDI were measured using dynamic light scattering (DLS), and the zeta
potential was determined using laser Doppler electrophoresis. The PDI is an indicator for particle size
distribution ranging from 0 (narrow distribution) to 1 (wide distribution).
2.7. Measurement
2.7.1. Calibration Curve
Cinnarizine standard solutions (10 to 500 ng/mL pure cinnarizine in 0.1 M HCl solution,
pH 1.2) were prepared for calibration measurement using reverse phase ultra-high performance
liquid chromatography (uHPLC). The HPLC system (Agilent technologies, Waldbronn, Germany)
consisted of Agilent Chem Station LC-DAD with UV detector. The method was developed using
Agilent Zorbax Eclipse Plus C18 (50 mm × 2.1 mm × 1.8 µm) column with gradient system of mobile
phases consisting of 0.1% formic acid in water as mobile phase A and 0.1% formic acid in acetonitrile
as mobile phase B (see Table 2). The flow rate was maintained at 0.3 mL/min. The column temperature
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was maintained at 40 ◦C and the detection wavelength used at 255 nm. The injection volume used was
10 µL for all measurements (standard solutions and samples). Agilent ChemStation software was used
to record and integrate responses of peak areas and retention time.
Table 2. Gradient system of mobile phases.
Time (min) %A %B
0 70 30
0.5 70 30
3 10 90
3.5 10 90
3.6 70 30
5 70 30
2.7.2. Drug Encapsulation Efficiency and Drug Release Study
Purified niosome suspensions and their respective dialysates were assayed for the encapsulation
efficiency, %EE. Isopropanol was used to disrupt the purified niosomes and filtered using 0.45 µm
syringe filter prior to HPLC measurements for quantification. %EE was calculated as the percentage of
total drug content (entrapped cinnarizine) after excluding free drug (non-entrapped cinnarizine) and
based on the calibration equation obtained (Figure 1).
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A modified method [24,25] for in vitro drug release study was performed using dialysis membrane
containing 5 mL of the purified niosome suspension (MF-based S60:Cho:ELP) immersed in a beaker
containing 200 mL of 0.1 M HCl solution (pH 1.2) as dissolution medium. The beaker was placed
in a water bath shaker at 37 ◦C and 50 rpm. At predetermined intervals, 1 mL of the dissolution
medium was withdrawn and then replaced with 1 mL of fresh 0.1 M HCl solution. The drug contents
in the dissolution medium were calculated using the HPLC measurements based on the calibration
equation obtained.
3. Results and Discussion
3.1. Morphological Analysis of Niosome Suspensions
The formation of freshly prepared niosomes for both film hydration (result not shown) and
microfluidic (see Figures 2 and 3) methods were confirmed by observation under light microscope
with magnification lens of 40× using Olympus BO61 (AxioCam MRc ZEISS) and real-time images
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were taken. Both blank niosomes and niosomes containing cinnarizine were formed successfully upon
hydration by distinctive round, circular shapes observed.
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multilamellar niosomes are produced by thin-film hydration method and this contributes to a higher
particle size distribution without size reduction process.
Table 3. Niosomes prepared by thin-film hydration method. * No niosomes formed or large aggregates
produced; ** no data obtained. For formulation composition, refer to Table 1.
Formulation z-Average (nm) Polydispersity Index(PDI) Zeta Potential (mV)
S60:Cho − * * *
S60:Cho + * * *
S60:Cho:ELP − 1256.3 ± 59.9 0.759 ± 0.110 **
S60:Cho:ELP + 3701.0 ± 414.6 0.518 ± 0.074 −1.82 ± 6.78
S60:Cho:RH40 − 827.5 ± 147.8 0.759 ± 0.128 −0.063 ± 18.5
S60:Cho:RH40 + 1244.0 ± 314.9 0.714 ± 0.106 0.039 ± 18.1
S60:Cho:HS15 − 5330.3 ± 1348.2 0.262 ± 0.223 −0.199 ± 20.1
S60:Cho:HS15 + 7320.7 ± 675.2 0.933 ± 0.115 0.118 ± 16.5
Non-ionic surfactants are amphiphilic molecules with different surface activity properties that
depend on the balance between their hydrophilic and hydrophobic regions. Surfactants with a
hydrophile-lipophile balance (HLB) value between 3 and 8 are suitable to form a bilayer-membrane
vesicle and are commonly referred to as water-in-oil (W/O) emulsifiers [15]. As non-ionic surfactants
have no charge groups in their hydrophilic head region, they are less toxic, more resistant against
pH changes in the gut, and with a wider compatibility compared to ionic surfactants. Other than
an HLB value of a non-ionic surfactant, the structure of a surfactant has a great impact on the
geometry formation of its vesicle attributed to critical packing parameters (CPPs) including the
hydrophobic group volume, critical hydrophobic group length, and the area of hydrophilic head
group [28]. Larger vesicles are formed when the hydrophilic portion of the molecule is decreased
relative to the hydrophobic portion as increasing in the alkyl chain length would result in an increase
in the CPP value [29]. As cinnarizine is a hydrophobic drug, it has the tendency to interact and to
be entrapped within the hydrophobic regions of the bilayer membrane of the multilamellar vesicles
formed by TFH method.
On the other hand, the results obtained in this study revealed that there was interaction between
the niosome vesicles and the hydrophobic drug which contributed to the smaller vesicle size. As the
drug surface activity is minor compared to the surfactants used, the decrease in vesicles’ size may be
due to the presence of the drug which implied a co-surfactant drug effect as described by Nikolakakis
et al. [30]. Therefore, cinnarizine incorporation within the niosome vesicles of equimolar of Span®
60 and cholesterol with co-surfactants is shown to decrease the size of niosomes. Cremophor®
RH40 as a hydrophilic co-surfactant exhibited the smallest vesicle size, this might be due to larger
molecular weight and higher surface activity, as compared to formulations comprised of co-surfactants:
Cremophor® ELP or Solutol® HS15. Accordingly, each co-surfactant performs differently based
on its structure, HLB, and properties. However, all vesicle size range is generally suitable for oral
administration dosage forms.
To the best of our knowledge, there has been little literature investigating the influence of
co-surfactant on niosomal formulations without post-preparation size reduction step. Therefore,
a size reduction process such as homogenization and sonication has to be carried out post preparation
of thin-film hydrated niosome vesicles to ensure homogeneity of niosome dispersions, this additional
step has drawbacks such as time consuming, low-cost effectiveness, requiring more characterisation
processes and affecting the drug loading.
Regarding the zeta potential of niosomes, a slight difference was found between formulations
with and without cinnarizine among the different formulations measured (Tables 3 and 4). The slight
positive charge obtained with cinnarizine entrapped niosomes suggested the basic characteristic of the
dissolved cinnarizine due to the presence of amine groups’ ionisation in the aqueous solution.
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Table 4. Size of niosomes prepared by microfluidic method. For formulation composition, refer to Table 1.
Formulation z-Average (nm) PDI ZP (mV)
S60:Cho − 155.6 ± 0.4 0.059 ± 0.011 −0.474 ± 9.7
S60:Cho + 217.9 ± 0.9 0.053 ± 0.009 −1.266 ± 9.6
S60:Cho:ELP − 350.3 ± 7.1 0.208 ± 0.012 5.272 ± 3.5
S60:Cho:ELP + 355.3 ± 1.5 0.202 ± 0.021 −4.486 ± 5.3
S60:Cho:RH40 − 224.7 ± 2.2 0.103 ± 0.019 −3.921 ± 4.3
S60:Cho:RH40 + 172.2 ± 0.4 0.209 ± 0.007 −1.803 ± 4.8
S60:Cho:HS15 − 310.8 ± 0.6 0.032 ± 0.051 −4.801 ± 3.6
S60:Cho:HS15 + 303.7 ± 1.9 0.011 ± 0.010 −0.764 ± 14.3
Because thin-film hydration method produced niosomes with variability with the presence of
the drug, it was decided to use a microfluidic system (which is mostly applied for preparation
of liposomes) to investigate its feasibility in production of niosomes with consistent properties,
taking into account there are very sparse literature for microfluidic technique and niosomes. It was
found that, generally, the size of niosome vesicles prepared by microfluidic method was very small
and indicating monodisperse suspension in comparison to niosome vesicles prepared by thin-film
hydration method. The NanoAssemblrTM Benchtop enables rapid formation of much smaller niosomes
by mixing two miscible fluids (aqueous and organic solvents) in a single-step process under focused
hydrodynamic flow in the architecture of the microfluidic cartridge which prevents suboptimal mixing
and heterogeneous nanoprecipitation of ingredients used, which is in agreement with Obeid et al. [31].
For niosomes prepared by microfluidic method (see Table 4), all formulations revealed noticeably
small particle size with a low PDI values (narrow distribution) as measured using zetasizer technique,
indicating large unilamellar vesicles (LUVs), and were manufactured successfully using microfluidic
method. These results demonstrated the potential use of microfluidic technique to prepare small
and uniform niosomes, minimising variable encapsulation efficiency, increasing homogeneity and
reproducibility of the formulation. The influence of cinnarizine inclusion with increased niosome
sizes can be seen in formulations without co-surfactant (F2) and Cremophor® ELP (F4) compared
with respective blank formulations (F1 and F3). In contrast, formulations with Cremophor® RH40
and Solutol® HS15 showed a decrease in particle size with cinnarizine inclusion. The slight change in
particle size for both with and without cinnarizine inclusion demonstrated an interaction between the
niosome vesicle and the hydrophobic drug.
3.3. Fourier-Transform Infra-Red (FTIR) Spectroscopy
Fourier-transform infra-red (FTIR) spectroscopy is useful for identifying principal peaks of
characteristic functional groups of a material as well as determining their changes within a specific
finger printing area [32]. In addition, the peak intensity is to establish concentration of a specific
bonds or functional groups. Fourier-transform infra-red spectra of individual material (Figure 4) and
freeze-dried niosomes were taken to determine their interactions and compatibilities [20].
The principle peaks of the cinnarizine pure drug (free base) were observed at 2959, 2936, 1597,
1490, 1448, 1134, 999, and 962 cm−1 (see Figure 5). Assignment for the major infra-red absorption
bands of cinnarizine (free base pure drug) is shown in the Table 5.
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Table 5. Principal peaks with assignments of cinnarizine pure drug.
Frequency (cm−1) Assignments
2959 CH stretching (aromatic, alkene, mono-substituted)
2936 CH stretch (aliphatic, alkane)
1597 C=C (aromatic stretch)
1490, 1448 CH2 (alkane)
1134 C-N stretching
999, 962 =C-H out of plane (out-of-plane) (aromatic, alkene)
Figure 6a–c show a comparison between same formulation composition with and without the
presence of cinnarizine. They demonstrate the interaction and incorporation of the drug within the
formulations. Similar peaks shown in formulations with and without cinnarizine generally indicate the
incorporation of surfactants, cholesterol, and co-surfactants to formation of niosomes. The entrapment
of cinnarizine within the vesicles can be seen with the disappearance of C-N stretch (1134 cm−1) of
the cinnarizine in all formulations (Figure 6). Apart from this C-N stretch, the C=C aromatic stretch
of the cinnarizine also disappeared in formulations with Cremophor® ELP (Figure 6a) and Solutol®
HS15 (Figure 6c) except for Cremophor® RH40. In Figure 6b, in comparison to Formulation 5 (without
cinnarizine), the spectrum of Formulation 6 revealed the presence of cinnarizine with the appearance
of its principal peak of C=C stretch, indicating that the drug was not able to be incorporated well
within the niosome vesicles. This might be due to the fact that the hydrophilic Cremophor® RH40
has the highest molecular weight among the other solubilising agents, is interacting and inhibiting
the incorporation of hydrophobic drug (cinnarizine). Similarly, microfluidic-prepared niosomes
(Figure 7a,b) demonstrated the entrapment of cinnarizine into the pre-formed niosomes.
3.4. Thermal Characteristics of Niosomes
Calorimetry technique in thermal analysis was used to study thermodynamic characteristics
(e.g., melting temperature, denaturation temperature, crystallization, and enthalpy change) [33]. In this
study, differential scanning calorimetry (DSC) was used to determine the temperatures and heats of
transitions for raw materials and freeze-dried niosomes. Heat flow data were obtained as a result of
dynamic measurement at a constant heating rate. The DSC curve taken for pure cinnarizine (Figure 8a)
showed a sharp endothermic peak at 123.05 ◦C. This peak either demolished in the freeze-dried
niosomes, indicating drug incorporation into niosome vesicles or broaden and shifted to a lower
temperature, suggesting changes in the structure arrangement and transformation to amorphous form.
Moreover, DSC curves for the freeze-dried thin film hydrated niosomes showed melting endothermic
peaks of Span® 60 (shifted from 56 ◦C to 46–47 ◦C) and cholesterol (but broaden and shifted from
149 ◦C to lower temperatures), indicating incomplete compatibility of the excipients used in film
hydration method based on the conditions applied. The use of lyoprotectant was reported to preserve
the integrity of the vesicles by inhibiting vesicle fusion and aggregation during the freezing stages [4].
The DSC curves in Figure 9 showed the mannitol endothermic peak at 167 ◦C and the demolition of
peaks similar to freeze-dried niosomes without mannitol.
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3.5. Drug Loading and Drug Release Studies
Low encapsulation efficiencies were found in all formulations prepared by thin film hydration
method (<20%; see Table 6) in preliminary studies. Similarly, noticeably low drug loading results
were obtained with microfluidic-prepared niosomes (data not shown). In addition, no improvement
on encapsulation efficiency can be se n in formulations with using higher drug concentrations
and remote drug loading techniques (vortex and water bath) used. The low %EE revealed the
occurrence of drug leakage as a result of the drug characteristics to remain dissolved in the acidic
medium and subsequently be removed during dialysis. Therefore, the highest encapsulation efficiency
obtained in microfluidic-prepared niosomes with Cremophor® ELP among other formulations was
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chosen for drug release study. The manufacture of the formulation was optimised to prepare empty
pre-formed niosomes followed by mixing with cinnarizine solution in 0.1 M HCl solution by using
water bath shaker.
Table 6. %EE a Microfluidic niosomes; b Thin-film hydration niosomes.
Formulation %EE a %EE b
S60:Cho:ELP + 8.9 19.5
S60:Cho:RH40 + 0.37 10.8
S60:Cho:HS15 + 0.53 8.3
The drug release at pre-determined intervals was measured for the optimised formulation in
this study. The in vitro drug release of cinnarizine from microfluidic-prepared niosomes (S60: Cho:
ELP) showed a noticeably low drug release for up to 2 h (Figure 10). A 50% release of encapsulated
cinnarizine was achieved at 24 h (data not shown). The slow release pattern shown suggested there
is an interaction between the hydrophobic drug and the amphiphilic niosome vesicles. Niosome
has been formulated to improve solubility of various poorly water-soluble drugs aiming to enhance
drug dissolution, and hence, a lower dose and less frequency of administration required. Moreover,
niosomes show the potential of protecting encapsulated cinnarizine within their vesicles in the acidic
environment (0.1 M HCl solution, pH 1.2) and releasing the drug slowly in the target absorption site
(stomach) at the same time. Empty pre-formed niosomes prepared by microfluidic method ensures the
uniformity of niosomes and the homogeneity (low PDI value) of the formulation to enhance predicted
drug release. The prepared niosomes show also promise to incorporate potent drugs for which the
small amount of drug released is being efficient and effective to produce the drug effect.
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4. Conclusions
In this study, the niosome characteristics influenced by preparation methods and the presence
of cinnarizine as a model for poorly water-soluble drug have been investigated. Niosome vesicles
comprised of equimolar of Span® 60 and cholesterol with different co-surfactants were successfully
prepared using both conventional thin-film hydration and microfluidic methods. The characterisation
studies demonstrated that the drug and co-surfactants have effects on niosomes characteristics
prepared by both thin-film hydration and microfluidic methods. Niosomes have shown potential for
prolonged release of cinnarizine in which the current multiple dosing can be reduced. Furthermore, a
smaller dose will be required to be taken as niosomes are capable of delivering to targeted absorption
site for higher bioavailability. The type of media used during niosome preparation should be taken
into consideration particularly for poorly water soluble drugs. Additionally, the icrofluidic system
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produced good quality vesicles even without co-surfactant (F1 and F2) and this method verified also
the simplified preparation step for desirable and consistent physiochemical properties of niosomes.
Therefore, it is a promising technique not only for liposomes as reported in literature but also for
niosomes as reported from this current research. This will open more doors for researchers including
authors of this research to apply microfluidic technique for niosomal production. Especially, it can
be used for industrial production of plain niosomes which can adapt different drugs as the niosomes
properties will mostly not be changed with addition of drugs at the same time ensuring the formulation
homogeneity and predicted release profiles.
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